CICATRIDINA

CICATRIDINA SUPPOSITORIES 10 PIECES

CICATRIDINA SUPPOSITORIES 10 PIECES

Skip to product information
1 of 1
  • Secure payment
  • Discreet and sanitized package
  • Fast and safe shipping

Description

Descriptive sheet

Cicatridine

suppositories

Description
CE Medical Device (EU Reg. 2017/745) Class IIb.
Adjuvant treatment of the repair processes of the anorectal canal after proctological surgery, internal and external hemorrhoids, proctitis, cryptitis, anal fissures, fissures, perianal fistulas.
It exerts its action thanks to the presence of hyaluronic acid, a mucopolysaccharide abundantly distributed in many body tissues. Hyaluronic acid, thanks to its ability to retain water, forms a film that hydrates, accelerates, and improves the process of tissue re-epithelialization and repair.

How to use
Wash your hands before and after using the medical device.
Peel a suppository from the blister along the cut line. Remove the suppository by pulling the two flaps of the blister. Insert the suppository rectally.

Adults: Use one suppository daily or as directed by your doctor, preferably in the evening before bed.
Avoid holding the suppository between your fingers for too long, as it may melt.
The duration of use depends on the evolution of symptoms. If necessary, CICATRIDINA suppositories can be used for extended periods. In any case, after 30 days of continuous use, discontinue treatment for one week.

Components
Hyaluronic acid sodium salt (5 mg), Centella asiatica lipolic extract, calendula lipolic extract, aloe vera lipolic extract, tea tree essential oil, semi-synthetic glycerides, BHT.

Warnings
The product is for rectal use only.
Keep out of reach of children.
Avoid contact with eyes.
Do not ingest.
If you are pregnant or breastfeeding, as no specific clinical studies have been conducted, consult your doctor before using the device.
Do not use in case of individual hypersensitivity to one of the components of the product.
Use, especially if prolonged, of all topical products may cause sensitization. If this occurs, or if you experience other side effects, discontinue use and consult your doctor or pharmacist.
There are no known interactions with other products, therefore it is advisable to consult your doctor before using CICATRIDINA suppositories in combination with other medical devices or drugs for rectal use.
Do not use in case of individual hypersensitivity to one of the components of the product.

Conservation
Store away from light and heat, preferably between 4°C and 25°C. Avoid temperatures above 30°C.
The expiry date refers to the product in intact packaging, stored correctly.
Do not use after the expiry date or if the package is opened or damaged.
Shelf life in intact packaging: 36 months.

Format
10 suppositories of 2 g.

Code 1002

CICATRIDINA

CICATRIDINA SUPPOSITORIES 10 PIECES

CICATRIDINA SUPPOSITORIES 10 PIECES

MINSAN code: 907116154
Previous price: €16,95
Regular price €16,95
Regular price €0,00 Sale price €16,95
-% Sold out
Tax included. Shipping calculated at checkout.
View full details

Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.